On Sep 28, major Wall Street analysts update their ratings for $Travere Therapeutic (TVTX.US)$, with price targets ranging from $17 to $23.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $18.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $23 to $19.
Guggenheim analyst Vamil Divan maintains with a buy rating, and adjusts the target price from $25 to $23.
Wedbush analyst Laura Chico maintains with a buy rating, and adjusts the target price from $16 to $17.
H.C. Wainwright analyst Ed Arce maintains with a buy rating, and adjusts the target price from $23 to $18.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Travere Therapeutics has announced a halt in enrollment for the pegtibatinase phase 3 HARMONY study due to manufacturing challenges, which is acknowledged as a delay in the commercial portfolio. The company anticipates that the trial could restart by 2026 at the earliest. Despite the setback, the program was previously not considered highly valuable by many, and the management has highlighted that the disruptions should not affect the trial design and enrollment. Consequently, it is anticipated that the influence on near-term sentiment will be relatively limited.
Travere Therapeutics has voluntarily paused enrollment in their Phase 3 HARMONY study of pegtibatinase due to challenges encountered with manufacturing scale-up. Analysts have expressed that while the pause is unfortunate, it is noteworthy as pegtibatinase was seen as an opportunity to diversify beyond Filspari. The anticipated launch has now been adjusted to fiscal 2030, based on projections that enrollment will recommence in 2026.
Following Travere Therapeutics' announcement of a voluntary pause on the Phase 3 HARMONY study for pegtibatinase in treating classical homocystinuria, or HCU, the timeline for larger patient enrollment and eventual commercialization is now anticipated to be significantly delayed, with expectations to resume study enrollment in 2026. Consequently, the probability of success for pegtibatinase has been moderately reduced, and the forecast for sales has been deferred by two years.
Here are the latest investment ratings and price targets for $Travere Therapeutic (TVTX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间9月28日，多家华尔街大行更新了$Travere Therapeutic (TVTX.US)$的评级，目标价介于17美元至23美元。
美银证券分析师Jason Zemansky维持买入评级，维持目标价18美元。
花旗分析师Yigal Nochomovitz维持买入评级，并将目标价从23美元下调至19美元。
Guggenheim分析师Vamil Divan维持买入评级，并将目标价从25美元下调至23美元。
韦德布什分析师Laura Chico维持买入评级，并将目标价从16美元上调至17美元。
H.C. Wainwright分析师Ed Arce维持买入评级，并将目标价从23美元下调至18美元。
此外，综合报道，$Travere Therapeutic (TVTX.US)$近期主要分析师观点如下：
由于制造方面的挑战，Travere Therapeutics宣布暂停聚乙二醇酶3期HARMONY研究的注册，这被认为是商业投资组合的延迟。该公司预计，该试验最早可能在2026年重启。尽管遇到了挫折，但许多人此前并不认为该计划具有很高的价值，管理层强调中断不应影响试验的设计和注册。因此，预计对短期情绪的影响将相对有限。
由于在扩大生产规模方面遇到挑战，Travere Therapeutics自愿暂停了聚乙二醇酶的3期HARMONY研究的注册。分析师表示，尽管暂停令人遗憾，但值得注意的是，聚乙二醇酶被视为在Filspari之外实现多元化的机会。根据预计招生将于2026年重新开始，预计的发射现已调整为2030财年。
在Travere Therapeutics宣布自愿暂停用于治疗传统高胱氨酸尿症（HCU）的聚乙二醇酶的3期HARMONY研究之后，现在预计扩大患者入组和最终商业化的时间表将大大推迟，预计将在2026年恢复研究入组。因此，聚乙二醇酶成功的可能性已适度降低，销售预测已推迟了两年。
以下为今日5位分析师对$Travere Therapeutic (TVTX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
